CL
MACK

CSS LLC’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

CSS LLC’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,398
Closed -$59K – 832
2016
Q2 		$59K Buy
+1,398
New +$76.2K ﹤0.01% 657

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

CSS LLC's MACK Position: Q3 2016 in Review

CSS LLC sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2016, closing a stake of 1,398 shares — an estimated $59K sold.

CSS LLC first reported a position in MACK in Q2 2016 and held it in 1 quarter. The position peaked at $59K in Q2 2016. 128 funds tracked by Wall St. Rank hold MACK as of Q3 2016.

  • CSS LLC reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
  • CSS LLC sold 1,398 Merrimack Pharmaceuticals, Inc. shares in Q3 2016, an estimated $59K.
  • CSS LLC first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2016 and held it in 1 quarter.
  • CSS LLC's Merrimack Pharmaceuticals, Inc. position peaked at $59K in Q2 2016.
  • 128 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2016.

Based on CSS LLC's 13F filing for Q3 2016, filed 14 Nov 2016.